non-hodgkin's%20lymphoma
NON-HODGKIN'S LYMPHOMA

Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies.
It is the most common hematologic cancer.
The most common subtypes are the diffuse large B-cell and follicular lymphoma. The subtypes are based on the malignant cell's morphology, genetic features, immunohistological characteristics, and stage of maturation.

Surgical Intervention

  • Further studies are needed to support use of bone marrow transplant (BMT) & stem cell transplant (SCT) in high-risk NHL patients
Bone Marrow Transplant (BMT)
  • Treatment of choice for patients with aggressive recurrent NHL
  • Studies show improved survival (20-40% long-term disease free rate) in high-risk patients
Stem Cell Transplantation (SCT)
  • May be considered in patients with indolent recurrent NHL, & aggressive noncontiguous stage II/III/IV NHL
    • Studies show an increase in the progression-free survival rate of patients given SCT as compared to those given chemotherapy alone
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 5 days ago
Gestational exposure to grain products fortified with folic acid appears to be linked to a lower risk of psychosis in offspring, according to a recent study.
Pearl Toh, 6 days ago
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
2 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 3 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.